Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income grows 12.6% year over year

Q4 FY2025 net income of CN¥639.96M (cash outflow) rose 12.6% year over year. Over 3 fiscal years it compounded at +11.7% a year.

Context

  • Net income amounted to 221.3% of revenue in FY2025, up 181.0 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -CN¥302.5M (-75.5%) for the fiscal year ending Dec 2026, a slowdown from the +212.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-CN¥639.96M— QoQ
Last fiscal yearDec 2025
-CN¥1.24B+212.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.6%——
1 year+212.7%-75.5%-288.2 pp
3-year CAGR+11.7%-48.8%-60.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CNY · from the cash flow

Latest · FY2025
(1.24B) CNY
Year-over-year change
-212.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +212.7% is the 2nd highest of 10, against a peer median of +14.0%.
  • Net income amounts to 221.3% of revenue for AAPG, versus a peer median of 66.1%.
AAPG Competitors
Net Income for AAPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥1.24B CNY+212.7%+11.7%221.3%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$294.88M USD+220.5%+13.6%42.0%
TNGXTango Therapeutics, Inc.LTM Sep 2026$208M USD+106.9%-2.1%—
VSTMVerastem, Inc.LTM Mar 2026$193.96M USD+30.3%+41.6%391.2%
ZLABZai Lab LimitedLTM Jun 2026$188.21M USD-11.4%-26.6%41.9%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$145.24M USD+14.0%+65.2%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$140.06M USD-54.4%+24.7%62.2%
NUVBNuvation Bio Inc.LTM Jun 2026$112.24M USD+155.3%+25.2%66.1%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$103.8M USD+0.5%-6.4%297.8%
IMRXImmuneering CorporationLTM Mar 2026$54.44M USD-11.9%+3.5%—
ANLAdlai Nortye Ltd.LTM Jun 2024$54.07M USD—-15.4%833.1%
Peer median (excluding AAPG) —+14.0%+8.6%66.1%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(832.25M)(887.17M)(932.86M)(395.26M)(1.24B)
Depreciation & Amortization28.33M62.92M93.2M93.17M86.48M
Deferred Income Tax00000
Stock-Based Compensation46.97M22.11M31.5M20.92M20.87M
Change in Working Capital(74.91M)104.41M(9.15M)110.97M(143.5M)
Accounts Receivables(53.97M)(388K)(91.54M)62.75M(169.8M)
Inventory(3.93M)(5.52M)(6.72M)9.57M(26.2M)
Accounts Payables024.7M(23.11M)19.52M14.77M
Other Working Capital(17.01M)85.62M112.22M19.13M37.72M
Other Non-Cash Items227.18M43.82M91.23M58.84M98.07M
Operating Cash Flow(604.68M)(653.92M)(726.08M)(111.36M)(1.17B)
Capital Expenditures(436.63M)(236.96M)(56.84M)(24.29M)(27.57M)
Acquisitions (Net)(36.2M)(20M)(20M)(25.52M)(43.34M)
Purchases of Investments(1.78B)(130M)0(312.23M)(929.14M)
Sales of Investments1.79B0000
Other Investing Activities(879K)(31.32M)88.03M(312.23M)0
Investing Cash Flow(466.52M)(384.61M)21.92M(362.04M)(1B)
Debt Repayment548.59M695.87M(13.36M)(145.34M)307.26M
Common Stock Issued1.3B0470.08M533.94M2.3B
Common Stock Repurchased(25.87M)(26.78M)(5.92M)0(9.04M)
Dividends Paid00000
Other Financing Activities(41.97M)(49.83M)(82.05M)(73.83M)(63.04M)
Financing Cash Flow1.78B619.27M368.75M314.77M2.54B
Effect of Forex Changes(23.28M)58.01M27.81M13.68M(63.24M)
Net Change in Cash686.91M(361.25M)(307.59M)(144.95M)302.68M
Free Cash Flow(1.04B)(890.88M)(782.92M)(135.65M)(1.2B)

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.